The Intersection of Digital Health and Artificial Intelligence Quality HTA is pleased to announce the article "The Intersection of Digital Health and Artificial Intelligence: Clearing the Cloud of Uncertainty", written by Pooyeh Grail and Bijan Farhoudi has been published by Digital Health Journal now. This study discusses the concepts of Digital Health and Artificial Intelligence [...]
The Canadian Trends in Drug Purchase - The drug purchase in 2021 was 8.3% (around $35.4 billion) higher than in 2020! Dr. Mina Tadrous et. al. estimated pharmaceutical drug purchases across Canada using IQVIA data stratified by sector (retail and hospital) and forecasted annual spending to 2023. They conducted a time series analysis to calculate [...]
Where are we in RWE? - The best relevant RWD source needs to be decided depending on the research question. However, we still need some standard RWE frameworks, particularly when it comes to the data from Digital Health technologies considering their significant role in generating RWD. Concato J et al. have shared some interesting points [...]
The Challenges of Regulatory and HTA Bodies in RWE - An interesting qualitative article by Silvers H. et al. about the perspectives on challenges, values & alignment of regulatory and HTA bodies. Great findings which could be an excellent opportunity for quantitative research if saturation was reached in all interviewed groups. Regulatory and HTA bodies need [...]
The Impact of COVID-19 on HTA - Regulation bodies and HTA agencies might need to use RWE more than ever and/or re-evaluate listed technologies using the RWE to cease reimbursement of low-value health technologies due to COVID-19. A great article about the Impact of the Pandemic on HTA by Paula K. Lorgelly and Amanda Adler: [...]
Happy 2021! Wishing you and your family a year full of health and happiness!
Real-World Evidence (RWE) In The HTA Process With the significant rise in treatment cost, an increase of the number of drugs and the pressure of the treatments for special conditions and rare diseases, the regulatory and reimbursement systems in Canada, as one of the pioneers in this area, are going to collaboratively publish a framework [...]
COVID 19, Interventional Studies - Sponsors and Health Interventions Interventional studies on COVID-19 are mainly sponsored by non-industry organizations. The industry has sponsored interventional studies only in the US, China and the UK so far which means the industry is not responsive in developing clinical trials. Considering the majority of studies are [...]
COVID-19, Interventional Studies Across the Globe Interventional studies on COVID-19 across the globe based on Global Clinical Trials and ClinicalTrials.gov by March 23, 2020 More is coming ...
Coronavirus (COVID-19) and Tax in Canada Coronavirus continues spreading across the globe including Canada. Three of the potential impacts of this pandemic on taxpayers, businesses, the provincial and federal governments. The economic impact of Coronavirus looks to be "epidemic" now but can be "pandemic" if controlling and prevention are not taken seriously. [...]